Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Ryan

Showing results (141-150 of 274) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapyJohn G Gribben, David P Ryan, Richard Boyajian, et al.
Cancer|October 25, 2011
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancerNils D Arvold, David P Ryan, Andrzej Niemierko, et al.
The Oncologist|January 31, 2019
Bridge: Person-Centered Collaborative Care for Patients with Serious Mental Illness and CancerKelly E Irwin, Elyse R Park, Lauren E Fields, et al.
Gastrointestinal Cancer Research : GCR|February 28, 2012
Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapyBrian M Alexander, Carlos Fernandez-Del Castillo, David P Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumorsJonathan Goldman, S Gail Eckhardt, Mitesh J Borad, et al.
The Oncologist|December 19, 2018
Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision AnalysisJin G Choi, Ryan D Nipp, Angela Tramontano, et al.
The Oncologist|January 3, 2012
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximabRaymond C Wadlow, Aram F Hezel, Thomas A Abrams, et al.
The Oncologist|October 12, 2020
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient SettingSienna M Durbin, Leyre Zubiri, Andrzej Niemierko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2017
Coping and Prognostic Awareness in Patients With Advanced CancerRyan D Nipp, Joseph A Greer, Areej El-Jawahri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumorsMatthew H Kulke, Emily K Bergsland, David P Ryan, et al.
Pageof 28

Showing results (141-150 of 274) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapyJohn G Gribben, David P Ryan, Richard Boyajian, et al.
Cancer|October 25, 2011
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancerNils D Arvold, David P Ryan, Andrzej Niemierko, et al.
The Oncologist|January 31, 2019
Bridge: Person-Centered Collaborative Care for Patients with Serious Mental Illness and CancerKelly E Irwin, Elyse R Park, Lauren E Fields, et al.
Gastrointestinal Cancer Research : GCR|February 28, 2012
Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapyBrian M Alexander, Carlos Fernandez-Del Castillo, David P Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumorsJonathan Goldman, S Gail Eckhardt, Mitesh J Borad, et al.
The Oncologist|December 19, 2018
Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision AnalysisJin G Choi, Ryan D Nipp, Angela Tramontano, et al.
The Oncologist|January 3, 2012
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximabRaymond C Wadlow, Aram F Hezel, Thomas A Abrams, et al.
The Oncologist|October 12, 2020
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient SettingSienna M Durbin, Leyre Zubiri, Andrzej Niemierko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2017
Coping and Prognostic Awareness in Patients With Advanced CancerRyan D Nipp, Joseph A Greer, Areej El-Jawahri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumorsMatthew H Kulke, Emily K Bergsland, David P Ryan, et al.
Pageof 28